Evidence map›Paper›PMID 34471535›Full record

ArticleTherapeutic advances in infectious disease

Impact of preemptive hospitalization on health outcomes at the temporary COVID-19 hospital in Mexico City: a prospective observational study.

Rafael Ricardo Valdez Vazquez, Héctor Gallardo-Rincón, Julieta Lomelín-Gascon, Rodrigo Ville Benavides, Linda Morales Juárez, Héctor Herrera Bello, Lidia Moreno Castañeda, Adrian Palacios Chavarria, Pablo Escalera Castillo, Luis Esteban Ramirez Gonzalez and 16 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 2 countries.

Rafael Ricardo Valdez VazquezTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Héctor Gallardo-RincónMexico Carlos Slim Foundation, Lago Zurich 245, Presa Falcon Building (Floor 20), Miguel Hidalgo, Mexico City 11529, Mexico.ORCID https://orcid.org/0000-0002-0811-4606
Julieta Lomelín-GasconTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Rodrigo Ville BenavidesTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-2158-831X
Linda Morales JuárezTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Héctor Herrera BelloTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Lidia Moreno CastañedaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Adrian Palacios ChavarriaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Pablo Escalera CastilloTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Luis Esteban Ramirez GonzalezTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Mónica Arboleya AvendañoTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Santiago Treviño BerlangaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Reyna Albertina Rosas LozaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Renate Victoria Álvarez WyssmannTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Erika Salinas LezamaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Alonso Gutiérrez RomeroTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
María Dolores Niembro OrtegaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Liudmila Villegas AcostaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Ailyn Cendejas SchotmanTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Jennifer Bertin MontoyaTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Andrea Gonzalez RodriguezTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Laura María Badel RamosTemporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
Luis Alberto Martinez-JuarezCarlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-7550-7867
Rodrigo Saucedo-MartínezCarlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
Alejandra MontoyaCarlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
Roberto Tapia-ConyerCarlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
Mexfam · MXLondon School of Hygiene & Tropical Medicine · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn response to the evolution of the coronavirus disease 2019 (COVID-19) pandemic, the admission protocol for the temporary COVID-19 hospital in Mexico City has been updated to hospitalize patients preemptively with an oxygen saturation (SpO

methodsThis prospective, observational, single-center study compared the progression and outcomes of patients who were preemptively hospitalized

resultsPreemptive hospitalization significantly reduced the requirement for oxygen therapy (odds ratio 0.45, 95% confidence interval 0.31-0.66), admission to the intensive care unit (ICU) (0.37, 0.23-0.60), requirement for invasive mechanical ventilation (IMV) (0.40, 0.25-0.64), and mortality (0.22, 0.10-0.50). Stratification by CALL score at admission showed that the benefit of preemptive hospitalization remained significant for patients requiring oxygen therapy (0.51, 0.31-0.83), admission to the ICU (0.48, 0.27-0.86), and IMV (0.51, 0.28-0.92). Mortality risk remained significantly reduced (0.19, 0.07-0.48).

conclusionPreemptive hospitalization reduced the rate of disease progression and may be beneficial for improving COVID-19 patient outcomes.

Indexed as

CALL scoreCOVID-19HFNCIMVMexicopreemptive hospitalizationpulse oximetrySARS-CoV-2temporary hospital

Identifiers

PMID34471535
PMCPMC8404663
OpenAlexW3198448302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.